Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odonate Therapeutics, Inc.ODT · Entity 132524 | Director · 10% owner | November 17, 2021 | November 19, 2021 |
| Rain Oncology Inc.RAIN · Entity 94695 | Director | January 26, 2024 | January 26, 2024 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | See Remarks | February 06, 2024 | February 08, 2024 |
| iTeos Therapeutics, Inc.ITOS · Entity 75965 | Director | June 11, 2024 | June 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odonate Therapeutics, Inc.
Report date November 17, 2021 · Filed November 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 445,756 |
Last balance in matching sequence
After 2021-11-19 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-11-17 · Sale · Disposed 170,000 · Balance 475,756 F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $1.97 to $2.95. F1: These securities are owned directly by the reporting person. The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC ("Boxer Capital"), (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) the reporting person, and (iv) Joe Lewis (collectively, the "Boxer Group") Each member of the Boxer Group other than the reporting person disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 4 · 2021-11-19 · Sale · Disposed 30,000 · Balance 445,756 F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $1.84 to $1.96. F1: These securities are owned directly by the reporting person. The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC ("Boxer Capital"), (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) the reporting person, and (iv) Joe Lewis (collectively, the "Boxer Group") Each member of the Boxer Group other than the reporting person disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,607,086 |
Last balance in matching sequence
After 2021-11-19 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2021-11-17 · Sale · Disposed 600,000 · Balance 5,007,086 F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $2.0026 to $2.4018. F2: These securities are owned directly by Boxer Capital and indirectly by the reporting person, Boxer Asset Management Inc. ("Boxer Management") and Joseph C. Lewis, by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 3 · 2021-11-18 · Sale · Disposed 250,000 · Balance 4,757,086 F2: These securities are owned directly by Boxer Capital and indirectly by the reporting person, Boxer Asset Management Inc. ("Boxer Management") and Joseph C. Lewis, by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 5 · 2021-11-19 · Sale · Disposed 150,000 · Balance 4,607,086 F2: These securities are owned directly by Boxer Capital and indirectly by the reporting person, Boxer Asset Management Inc. ("Boxer Management") and Joseph C. Lewis, by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by the reporting person. The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC ("Boxer Capital"), (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) the reporting person, and (iv) Joe Lewis (collectively, the "Boxer Group") Each member of the Boxer Group other than the reporting person disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F2: These securities are owned directly by Boxer Capital and indirectly by the reporting person, Boxer Asset Management Inc. ("Boxer Management") and Joseph C. Lewis, by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $1.97 to $2.95.
F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $2.0026 to $2.4018.
F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $1.84 to $1.96.
Rain Oncology Inc.
Report date January 26, 2024 · Filed January 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 1
1 source rowRow 1 · 2024-01-26 · Other · Disposed 79,726 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-26 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Tyra Biosciences, Inc.
Report date February 06, 2024 · Filed February 08, 2024
Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, MVA Investors, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 85,939 |
Reported balance
After 2024-02-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-02-06 · Grant · Acquired 63,412 · Balance 85,939 F1: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 705,280 |
Reported balance
After 2024-02-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-06 · Grant · Acquired 705,280 · Balance 705,280 F3: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 6,448,359 |
Reported balance
Holding disclosure · report date 2024-02-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,448,359 F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F3: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date.
iTeos Therapeutics, Inc.
Report date June 11, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-06-11 | Direct | 24,200 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 24,200 · Balance 24,200 |
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 25, 2024
Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, MVA Investors, LLC, Dissanayake Shehan Bharatha, Fuglesang Christopher, Braslyn Ltd., Lockend Five, LLC
Section 16 reporting ended · disclosed 2024-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-01-23 · Disposition to issuer · Disposed 287,866 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-01-23 · Disposition to issuer · Disposed 203,754 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 3,135,966 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2024-01-23 · Disposition to issuer · Disposed 30,518 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-01-23 · Disposition to issuer · Disposed 3,201,440 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-23 · Disposition to issuer · Disposed 332,809 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-23 · Disposition to issuer · Disposed 3,578,036 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | 0 |
Reported balance
After 2024-01-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-23 · Disposition to issuer · Disposed 1,413,475 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").
F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.
F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.
F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.
F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.
F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.
PMV Pharmaceuticals, Inc.
Report date September 25, 2020 · Filed September 29, 2020
Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, MVA Investors, LLC
Section 16 reporting ended · disclosed 2020-09-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,268,236 |
Last balance in matching sequence
After 2020-09-29 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-09-25 · Purchase · Acquired 950,000 · Balance 950,000 F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Row 2 · 2020-09-29 · Conversion · Acquired 586,099 · Balance 1,536,099 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Row 3 · 2020-09-29 · Conversion · Acquired 732,137 · Balance 2,268,236 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,837 |
Last balance in matching sequence
After 2020-09-29 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 4 · 2020-09-29 · Conversion · Acquired 32,708 · Balance 32,708 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 5 · 2020-09-29 · Conversion · Acquired 28,129 · Balance 60,837 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-09-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-09-29 · Conversion · Disposed 586,099 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-09-29 · Conversion · Disposed 32,708 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-09-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-09-29 · Conversion · Disposed 732,137 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-09-29 · Conversion · Disposed 28,129 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.
F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Pandion Therapeutics, Inc.
Report date July 21, 2020 · Filed July 21, 2020
Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., Braslyn Ltd., LEWIS JOSEPH, MVA Investors, LLC
Section 16 reporting ended · disclosed 2020-07-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,107,513 |
Last balance in matching sequence
After 2020-07-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-07-21 · Conversion · Acquired 1,385,291 · Balance 1,385,291 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 3 · 2020-07-21 · Purchase · Acquired 722,222 · Balance 2,107,513 F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 23,622 |
Reported balance
After 2020-07-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-07-21 · Conversion · Acquired 23,622 · Balance 23,622 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-21 · Conversion · Disposed 7,064,136 · Balance 0 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-21 · Conversion · Disposed 120,460 · Balance 0 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Tango Therapeutics, Inc.
Report date November 06, 2024 · Filed November 08, 2024
Jointly reported with Boxer Capital Management, LLC
Section 16 reporting ended · disclosed 2024-11-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,610,642 |
Reported balance
After 2024-11-06 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-11-06 · Sale · Disposed 3,080,000 · Balance 3,610,642 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.3955, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of an account holding such securities. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Mr. Davis is the Managing Member of BCM and has voting and dispositive power over securities beneficially owned by BCM, but disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 108,793 |
Reported balance
Holding disclosure · report date 2024-11-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 108,793 F3: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors, but disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. BCM disclaims beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,988,450 |
Reported balance
Holding disclosure · report date 2024-11-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,988,450 F4: These securities are owned directly by BCTG Holdings, LLC ("BCTG"). MVA Investors is a member of BCTG. Mr. Davis is a member of the investment committee of BCTG. Mr. Davis disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any. BCM disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.3955, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These securities are held indirectly by Boxer Capital Management, LLC ("BCM") as the investment manager of an account holding such securities. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Mr. Davis is the Managing Member of BCM and has voting and dispositive power over securities beneficially owned by BCM, but disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, if any.
F3: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors, but disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. BCM disclaims beneficial ownership of these securities.
F4: These securities are owned directly by BCTG Holdings, LLC ("BCTG"). MVA Investors is a member of BCTG. Mr. Davis is a member of the investment committee of BCTG. Mr. Davis disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any. BCM disclaims beneficial ownership of these securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2023 Filed Oct 11, 2023 19:22 UTC Amendment | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantPrefunded Warrant · Derivative | 2,340,579 | $5.15 | $12,053,747.79 |
DisclosureSEC source: 0000895345-23-000573 · form4.xml · derivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · Director · See remarks Boxer Asset Management Inc. · CIK 0001465836 · Director · See remarks LEWIS JOSEPH · CIK 0001015747 · Director · See remarks MVA Investors, LLC · CIK 0001468223 · Director · See remarks Davis Aaron I. · CIK 0001465914 · Director · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,340,579 Underlying: Common Stock · 2,340,579 shares Expires not disclosed F6 · derivative.exercise_price: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F6 · derivative.exercise_date: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F6 · derivative.expiration_date: The prefunded warrants have an exercise price of $0.001 per share of Common Stock and are immediately exercisable and remain exercisable until exercised in full, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Asset Management Inc. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Oct 11, 2023 19:22 UTC Amendment | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 475,000 | $5.15 | $2,446,250.00 |
DisclosureSEC source: 0000895345-23-000573 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · Director · See remarks Boxer Asset Management Inc. · CIK 0001465836 · Director · See remarks LEWIS JOSEPH · CIK 0001015747 · Director · See remarks MVA Investors, LLC · CIK 0001468223 · Director · See remarks Davis Aaron I. · CIK 0001465914 · Director · See remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 743,542 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. F1 · ownership.nature: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 21:05 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001104659-23-090698 · tm2323614-3_4seq1.xml · derivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: This option represents a right to purchase a total of 35,000 shares of the Issuer's common stock, which will vest in full on the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 19:52 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 22,383 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001209191-23-037587 · doc4.xml · derivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,383 Underlying: Common Stock · 22,383 shares Expires 2033-06-13 Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:32 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0000899243-23-015012 · doc4.xml · derivative · entry 5 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2023-06-06 F5 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:32 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015012 · doc4.xml · nonDerivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| May 22, 2023 Filed May 24, 2023 20:05 UTC | Rain Oncology Inc. RAIN · Entity 94695 | SaleCommon Stock | 995,000 | $1.25 | $1,243,750.00 |
DisclosureSEC source: 0000895345-23-000356 · form4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · See remarks. Boxer Asset Management Inc. · CIK 0001465836 · See remarks LEWIS JOSEPH · CIK 0001015747 · See remarks. Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152,212 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.30, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein F3 · ownership.direct: These securities are owned indirectly by Boxer Management and Joe Lewis, by virtue of their ownership of Boxer Capital. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 02:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 65,568 | $13.40 | $878,611.20 |
DisclosureSEC source: 0000895345-23-000107 · form4.xml · nonDerivative · entry 2 MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,527 F1 · ownership.direct: These securities are held directly by MVA Investors, LLC ("MVA Investors"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) MVA Investors, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) Aaron I. Davis, (v) Joseph C. Lewis and (vi) Siddarth Subramony (collectively, the "Boxer Group"), and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 02:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 200,000 | $13.10 | $2,620,000.00 |
DisclosureSEC source: 0000895345-23-000107 · form4.xml · nonDerivative · entry 1 MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,095 F1 · ownership.direct: These securities are held directly by MVA Investors, LLC ("MVA Investors"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) MVA Investors, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) Aaron I. Davis, (v) Joseph C. Lewis and (vi) Siddarth Subramony (collectively, the "Boxer Group"), and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 7,520 | $0.00 Strike: $45.66 | $0.00 |
DisclosureSEC source: 0001214659-23-001050 · marketforms-58280.xml · derivative · entry 2 Davis Aaron I. · CIK 0001465914 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 4,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001050 · marketforms-58280.xml · nonDerivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,517 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 16:30 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseNon-Voting Common Stock · Derivative | 400,000 | $5.83 | $2,332,000.00 |
DisclosureSEC source: 0000899243-22-035366 · doc4.xml · derivative · entry 2 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,422,489 Underlying: Common Stock · 400,000 shares Expires not disclosed F2 · derivative.exercise_price: Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.exercise_date: Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.expiration_date: Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, (iv) MVA Investors, LLC and (v) Joe Lewis (collectively, the "Boxer Group"). The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 16:30 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseCommon Stock | 972,212 | $5.83 | $5,667,995.96 |
DisclosureSEC source: 0000899243-22-035366 · doc4.xml · nonDerivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,147,212 F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, (iv) MVA Investors, LLC and (v) Joe Lewis (collectively, the "Boxer Group"). The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 21:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 70,000 | $4.65 | $325,227.00 |
DisclosureSEC source: 0000899243-22-033595 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,123,642 F2 · ownership.direct: These securities are owned directly by Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 21:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 50,000 | $4.43 | $221,640.00 |
DisclosureSEC source: 0000899243-22-033595 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,524 F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC ("Boxer Capital"), (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) BCTG Holdings, LLC, (v) MVA Investors and (vi) Aaron I. Davis (collectively, the "Boxer Group"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 21:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 117,000 | $4.25 | $497,706.30 |
DisclosureSEC source: 0000899243-22-033595 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,524 F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $4.0500 to $4.2631. F1 · ownership.direct: These securities are owned directly by MVA Investors, LLC ("MVA Investors"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC ("Boxer Capital"), (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) BCTG Holdings, LLC, (v) MVA Investors and (vi) Aaron I. Davis (collectively, the "Boxer Group"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 19:47 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 17,538 | $0.00 Strike: $18.78 | $0.00 |
DisclosureSEC source: 0001209191-22-036133 · doc4.xml · derivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,538 Underlying: Common Stock · 17,538 shares Expires 2032-06-09 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 08, 2022 Filed Jun 28, 2022 20:30 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-22-024402 · doc4.xml · derivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year from June 8, 2022, subject to the Reporting Person's continuous service on the board of directors as of each such vesting date. Read SEC document |
| June 01, 2022 Filed Aug 19, 2022 17:40 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0000899243-22-029321 · doc4.xml · derivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's common stock, which will vest in full on June 1, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 11, 2022 Filed May 11, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 337,109 | $18.25 | $6,151,801.01 |
DisclosureSEC source: 0000899243-22-017712 · doc4.xml · nonDerivative · entry 6 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,154,058 F6 · price: Reflects the weighted average sale price. Boxer Capital effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. Boxer Capital hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $18.5817 to $17.6656. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| May 11, 2022 Filed May 11, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 891 | $17.53 | $15,621.01 |
DisclosureSEC source: 0000899243-22-017712 · doc4.xml · nonDerivative · entry 5 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,491,167 F5 · price: Reflects the weighted average sale price. Boxer Capital effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. Boxer Capital hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $17.59 to $17.5268. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| May 10, 2022 Filed May 11, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 4,850 | $24.77 | $120,111.71 |
DisclosureSEC source: 0000899243-22-017712 · doc4.xml · nonDerivative · entry 4 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,492,058 F4 · price: Reflects the weighted average sale price. Boxer Capital effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. Boxer Capital hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $24.8245 to $24.7173. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| May 10, 2022 Filed May 11, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 95,150 | $25.18 | $2,395,857.97 |
DisclosureSEC source: 0000899243-22-017712 · doc4.xml · nonDerivative · entry 3 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,496,908 F3 · price: Reflects the weighted average sale price. Boxer Capital effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. Boxer Capital hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $25.8763 to $24.9379. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 200,000 | $23.47 | $4,693,120.00 |
DisclosureSEC source: 0000899243-22-017712 · doc4.xml · nonDerivative · entry 2 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,592,058 F2 · price: Reflects the weighted average sale price. Boxer Capital effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. Boxer Capital hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $24.10 to $23.16430. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 25,000 | $22.91 | $572,722.50 |
DisclosureSEC source: 0000899243-22-017712 · doc4.xml · nonDerivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,792,058 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| May 02, 2022 Filed May 2, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 92,700 | $27.53 | $2,552,327.64 |
DisclosureSEC source: 0000899243-22-016203 · doc4.xml · nonDerivative · entry 5 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,817,058 F4 · price: Reflects the weighted average sale price. Boxer Capital effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. Boxer Capital hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $28.00 to $27.14178. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| May 02, 2022 Filed May 2, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 7,300 | $26.91 | $196,406.50 |
DisclosureSEC source: 0000899243-22-016203 · doc4.xml · nonDerivative · entry 4 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,909,758 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| April 29, 2022 Filed May 2, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 115,000 | $27.01 | $3,106,667.50 |
DisclosureSEC source: 0000899243-22-016203 · doc4.xml · nonDerivative · entry 3 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,917,058 F3 · price: Reflects the weighted average sale price. Boxer Capital effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. Boxer Capital hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $27.2107 to $26.6900. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| April 29, 2022 Filed May 2, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 10,000 | $28.22 | $282,154.00 |
DisclosureSEC source: 0000899243-22-016203 · doc4.xml · nonDerivative · entry 2 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,032,058 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| April 28, 2022 Filed May 2, 2022 21:15 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 150,000 | $27.40 | $4,110,315.00 |
DisclosureSEC source: 0000899243-22-016203 · doc4.xml · nonDerivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,042,058 F2 · price: Reflects the weighted average sale price. Boxer Capital effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. Boxer Capital hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $27.88464 to $27.16000. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 21:00 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | PurchaseCommon Stock | 20,000 | $32.85 | $656,980.00 |
DisclosureSEC source: 0000899243-22-012152 · doc4.xml · nonDerivative · entry 4 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,192,058 F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:00 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | PurchaseCommon Stock | 5,000 | $33.43 | $167,139.00 |
DisclosureSEC source: 0000899243-22-012152 · doc4.xml · nonDerivative · entry 3 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,172,058 F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:00 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | PurchaseCommon Stock | 3,700 | $33.09 | $122,432.26 |
DisclosureSEC source: 0000899243-22-012152 · doc4.xml · nonDerivative · entry 2 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,167,058 F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 21:00 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | PurchaseCommon Stock | 21,300 | $31.88 | $678,937.50 |
DisclosureSEC source: 0000899243-22-012152 · doc4.xml · nonDerivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,163,358 F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) the reporting person, and (iv) Joe Lewis. The reporting person disclaims beneficial ownership of these securities to the extent he does not have a pecuniary interest therein. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 18:17 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 3,688 | $0.00 Strike: $124.31 | $0.00 |
DisclosureSEC source: 0001214659-22-000842 · marketforms-55080.xml · derivative · entry 2 Davis Aaron I. · CIK 0001465914 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688 Underlying: Common Stock · 3,688 shares Expires 2032-01-13 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 18:17 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-000842 · marketforms-55080.xml · nonDerivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,073 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 2,517 | $45.48 | $114,467.37 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 14 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 11,199 | $44.44 | $497,701.48 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 13 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,517 F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 3,138 | $43.36 | $136,062.42 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 12 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,716 F6 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221. F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 29,623 | $41.84 | $1,239,485.57 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 11 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,854 F5 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440. F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 7,483 | $45.48 | $340,309.63 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 10 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,717,259 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 33,297 | $44.44 | $1,479,771.96 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 9 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,724,742 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 9,366 | $43.36 | $406,109.76 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,758,039 F6 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 88,054 | $41.84 | $3,684,355.47 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,767,405 F5 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 731 | $50.63 | $37,013.31 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,477 F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 1,682 | $49.37 | $83,048.58 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,208 F4 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716. F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 23,353 | $47.63 | $1,112,245.01 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,890 F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617. F2 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 17,173 | $50.63 | $869,534.25 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855,459 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 39,481 | $49.37 | $1,949,354.63 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,872,632 F4 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:20 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | SaleCommon Stock | 432,903 | $47.65 | $20,626,182.92 |
DisclosureSEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,912,113 F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.